GSK is taking its mRNA-based seasonal influenza vaccine candidate to the next level. The pharma giant announced it will advance the shot into a late-stage (Phase 3) trial after mid-stage data showed it produced stronger immune responses compared to currently approved standard- and high-dose flu vaccines. The move signals growing confidence in mRNA technology as a platform for tackling infectious diseases beyond COVID-19.

This development puts GSK in the race alongside other players exploring next-generation flu vaccines, with mRNA's speed and flexibility offering potential advantages in keeping up with rapidly evolving influenza strains.

Key Takeaways:

• GSK's mRNA flu vaccine outperformed both standard- and high-dose approved flu shots in mid-stage (Phase 2) trials on immune response measures
• The candidate is now advancing to a late-stage (Phase 3) trial — the final hurdle before potential regulatory approval
• mRNA vaccine technology, proven during the COVID-19 pandemic, is increasingly being applied to seasonal infectious diseases like influenza

Why it matters: If the late-stage trial succeeds, GSK's mRNA flu vaccine could redefine the standard of care for seasonal influenza — offering stronger protection and potentially faster updates to match new strains, benefiting millions of people vaccinated each year.